Acuta Capital Partners as of Sept. 30, 2023
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 43 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Replimune Group Call Option (REPL) | 42.9 | $267M | 151k | 1766.00 | |
| Sarepta Therapeutics Call Option (SRPT) | 35.6 | $221M | 16k | 13783.00 | |
| Taysha Gene Therapies Com Shs (TSHA) | 1.9 | $12M | 3.8M | 3.16 | |
| Apellis Pharmaceuticals (APLS) | 1.5 | $9.3M | 245k | 38.04 | |
| Aadi Bioscience (AADI) | 1.4 | $9.0M | 1.8M | 4.84 | |
| Praxis Precision Medicines I | 1.2 | $7.7M | 4.5M | 1.71 | |
| Rayzebio | 1.2 | $7.6M | 345k | 22.20 | |
| Rocket Pharmaceuticals (RCKT) | 1.2 | $7.4M | 362k | 20.49 | |
| Ventyx Biosciences (VTYX) | 1.1 | $7.1M | 205k | 34.73 | |
| Disc Medicine (IRON) | 1.0 | $6.5M | 138k | 46.98 | |
| Kura Oncology (KURA) | 1.0 | $6.4M | 702k | 9.12 | |
| Cymabay Therapeutics | 1.0 | $6.2M | 418k | 14.91 | |
| Vaxcyte (PCVX) | 1.0 | $6.2M | 121k | 50.98 | |
| Immunovant (IMVT) | 0.8 | $5.0M | 129k | 38.39 | |
| Syndax Pharmaceuticals (SNDX) | 0.7 | $4.3M | 297k | 14.52 | |
| Hillevax (HLVX) | 0.6 | $3.6M | 270k | 13.45 | |
| Alkermes SHS (ALKS) | 0.6 | $3.5M | 127k | 28.01 | |
| Miragen Therapeutics (VRDN) | 0.6 | $3.4M | 224k | 15.34 | |
| Celldex Therapeutics Com New (CLDX) | 0.5 | $3.4M | 122k | 27.52 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.4 | $2.8M | 94k | 29.74 | |
| Terns Pharmaceuticals (TERN) | 0.4 | $2.8M | 555k | 5.03 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.4 | $2.4M | 300k | 7.99 | |
| Ikena Oncology (IKNA) | 0.4 | $2.4M | 551k | 4.33 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.3 | $2.1M | 323k | 6.47 | |
| Olema Pharmaceuticals (OLMA) | 0.3 | $1.9M | 153k | 12.35 | |
| Verastem Com New (VSTM) | 0.3 | $1.9M | 230k | 8.13 | |
| Enliven Therapeutics (ELVN) | 0.2 | $1.4M | 104k | 13.66 | |
| Dyne Therapeutics (DYN) | 0.2 | $1.3M | 147k | 8.96 | |
| Kronos Bio (KRON) | 0.2 | $934k | 719k | 1.30 | |
| Aclaris Therapeutics (ACRS) | 0.1 | $834k | 122k | 6.85 | |
| Brainstorm Cell Therapeutics Com New Put Option | 0.1 | $825k | 2.5k | 330.00 | |
| Biomea Fusion (BMEA) | 0.1 | $550k | 40k | 13.76 | |
| 89bio (ETNB) | 0.1 | $522k | 34k | 15.44 | |
| Ionis Pharmaceuticals (IONS) | 0.1 | $513k | 11k | 45.36 | |
| Leap Therapeutics Com New (LPTX) | 0.1 | $489k | 354k | 1.38 | |
| Rezolute Com New (RZLT) | 0.1 | $409k | 310k | 1.32 | |
| Cellectar Biosciences Com New (CLRB) | 0.1 | $320k | 121k | 2.64 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 0.0 | $252k | 5.0k | 50.42 | |
| An2 Therapeutics (ANTX) | 0.0 | $214k | 13k | 16.08 | |
| Marinus Pharmeceuticals Com New (MRNS) | 0.0 | $157k | 20k | 8.05 | |
| Mersana Therapeutics (MRSN) | 0.0 | $127k | 100k | 1.27 | |
| Glycomimetics (GLYC) | 0.0 | $41k | 28k | 1.50 | |
| Nuvation Bio *w Exp 07/07/2027 (NUVB.WS) | 0.0 | $9.1k | 91k | 0.10 |
